79201-37-9Relevant academic research and scientific papers
A catalytic approach to the MH-031 lactone: Application to the synthesis of geralcin analogs
Tello-Aburto, Rodolfo,Lucero, Alyssa N.,Rogelj, Snezna
supporting information, p. 6266 - 6268 (2014/12/11)
A concise, 5-step synthesis of the hepatoprotective lactone MH-031 was achieved. Our approach utilizes several catalytic processes, namely, a Rauhut-Currier reaction, a chemoselective Fisher esterification, and a ring closing metathesis. Further elaboration of this lactone yielded the hydrazide natural product geralcin A and dihydrogeralcin B, a saturated analog of geralcin B. Biological evaluation of the latter indicated that the presence of the enehydrazide moiety in geralcin B is critical for anticancer activity.
Total synthesis of geralcin A, a representative of a new family of hydrazine-containing natural products
Le Goff, Géraldine,Roulland, Emmanuel,Ouazzani, Jamal
supporting information, p. 5299 - 5301 (2013/09/12)
The first total synthesis of geralcin A (2), a naturally occurring α,β-unsaturated γ-lactonohydrazide produced by Streptomyces sp. LMA-545, was achieved according to the hypothetical biosynthesis we have previously published. MH-031 (1), the plausible nat
2-(6-Carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation
Ghali,Venton,Hung,Le Breton
, p. 1056 - 1060 (2007/10/02)
Two new azaprostanoids, a hydrazone(3) and hydrazide (4), have been prepared by the condensation of 2-(6-carboxyhexyl)cyclopentanone with n-hexylhydrazine and caproic acid hydrazide. Preliminary results with the stable hydrazide 4 indicate that it inhibits arachidonic acid (AA) induced human platelet aggregation and that, unlike 13-azaprostanoic acid (1), its site of action is at the cyclooxygenase level. Results with the unstable hydrazone derivative 3 indicate it to be a potent and time-dependent inhibitor of AA-induced human platelet aggregation, with its site of action also at the cyclooxygenase level.
